GlassScriptPhysician profile
Lydia Clements
NPI 1942618962
$1,272.86
in general payments reported to CMS, 2019-2025
23 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $433 · 2021: $430 · 2022: $124 · 2023: $15.69 · 2024: $22.51 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $175.92 | 2021 | |
| Amgen INC. | $162.70 | 2020 | |
| Secura Bio, INC. | $141.18 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $122.80 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $104.55 | 2020-2021 | |
| Kite Pharma, INC. | $99.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $82.45 | 2020-2021 | |
| Genentech USA, INC. | $44.40 | 2019-2022 | |
| Puma Biotechnology, INC. | $42.18 | 2020 | |
| Incyte Corporation | $40.32 | 2020-2021 | |
| Genzyme Corporation | $37.28 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.08 | 2020-2021 | |
| Celgene Corporation | $28.57 | 2025 | Reblozyl |
| Syndax Pharmaceuticals, INC. | $22.75 | 2025 | Revuforj |
| Merck Sharp & Dohme LLC | $20.96 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $17.45 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.07 | 2022 | |
| Pfizer INC. | $15.69 | 2023 | |
| Abbvie INC. | $14.03 | 2021 | |
| Seagen INC. | $13.76 | 2020 | |
| Sobi, INC | $13.75 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Clovis Oncology, INC. | $8.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Clements listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.